Danny has over 20 years of experience in developing regulatory strategies, leading registration and supporting the launch of pharmaceutical and biologic products in Canada at Cato Research, Shire, Avir Pharma / Laboratoire Riva and, since January 2022 at JAMP Pharma as Vice-President, Regulatory Affairs. Danny also serves as co-leader for the Regulatory Affairs option of the master’s of pharmaceutical science and drug development program at the University of Montreal and sits on the Board of Directors of the Canadian Association of Professionals in Regulatory Affairs (CAPRA), where he has been a volunteer, since 2003, on the symposia committee. Danny is also an author of a book published by RAPS, entitled Fundamentals of Canadian Regulatory Affairs. He holds master’s degree in pharmaceutical science and Drug Development (Regulatory Affairs) from the University of Montreal, an MBA from Laval University, and the RAC and CCPE certifications. His vision: to optimize time-to-market for the sake of providing safe and effective options to patients.
